...
首页> 外文期刊>Nanobiotechnology, IET >Preparation and characterisation of atorvastatin and curcumin-loaded chitosan nanoformulations for oral delivery in atherosclerosis
【24h】

Preparation and characterisation of atorvastatin and curcumin-loaded chitosan nanoformulations for oral delivery in atherosclerosis

机译:阿托伐他汀和姜黄素负载的壳聚糖纳米制剂的制备与表征,用于动脉粥样硬化的口服给药

获取原文
获取原文并翻译 | 示例
           

摘要

Atorvastatin known to be a potential inhibitor of HMG-CoA reductase involved in the synthesis of cholesterol. It is touted as miracle drug due to its profound effect in decreasing the low-density lipoproteins in blood. Unfortunately, the high dosage used poses side-effects relatively in comparison to other statins. On the other hand, curcumin has a diverse therapeutic potential in health and disease. However, the poor aqueous solubility and low bioavailability hinders the therapeutic potential of it when administrated orally. Therefore, it was thought to minimise the frequency of atorvastatin doses to avoid the possibility of drug resistance and also to overcome the limitations of curcumin for desirable therapeutic effects by using nanocarriers in drug delivery. In this investigation, synergistic effect of atorvastatin and curcumin nanocarriers was encapsulated by chitosan polymer. The chitosan nanocarriers prepared by ionic gelation method were characterised for their particle size, zeta potential, and other parameters. The drug-loaded nanocarriers exhibited good encapsulation efficiency (74.25%) and showed a slow and sustained release of atorvastatin and curcumin 60.36 and 61.44%, respectively, in a span of 48 h. The drug-loaded nanocarriers found to be haemocompatible and qualified for drug delivery in atherosclerosis.
机译:阿托伐他汀被认为是参与胆固醇合成的HMG-CoA还原酶的潜在抑制剂。由于其在减少血液中低密度脂蛋白方面的深远影响,因此被誉为奇迹药物。不幸的是,与其他他汀类药物相比,所用的高剂量相对具有副作用。另一方面,姜黄素在健康和疾病方面具有多种治疗潜力。但是,水溶性差和生物利用度低阻碍了口服时的治疗潜力。因此,据认为通过在药物递送中使用纳米载体,最小化阿托伐他汀剂量的频率以避免耐药性的可能性,并且还克服了姜黄素对于期望的治疗效果的限制。在这项研究中,壳聚糖聚合物包裹了阿托伐他汀和姜黄素纳米载体的协同作用。通过离子凝胶法制备的壳聚糖纳米载体的粒径,ζ电势和其他参数进行了表征。载有药物的纳米载体在48小时内显示出良好的包封效率(74.25%),并分别缓慢且持续释放阿托伐他汀和姜黄素60.36和61.44%。发现载有药物的纳米载体具有血液相容性,并且适合在动脉粥样硬化中递送药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号